We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of Magnetic Resonance (MR) Simulation for Treatment Planning

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00314496
First Posted: April 14, 2006
Last Update Posted: February 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
  Purpose

Retrospectively have access to MR images of patients to develop software that:

  1. segment images
  2. convert MR values to electron density and then
  3. entered into a dose calculation system

The project involves software development of data that is already available. No intervention is made at this point.


Condition
Healthy

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Development of MR Simulation for Treatment Planning

Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 10
Study Start Date: September 2005
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patient with conform histological diagnosis of glioblastoma multiforme signed the consent forms and were willing to go for curative radiation treatment with temozolomide
Criteria

Inclusion Criteria:

  • Subject 18 years of age and older
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314496


Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00314496     History of Changes
Other Study ID Numbers: EX-0004
First Submitted: April 11, 2006
First Posted: April 14, 2006
Last Update Posted: February 25, 2016
Last Verified: January 2012